Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73


WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.

Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massagué J.

Cell. 2009 Jul 10;138(1):51-62. doi: 10.1016/j.cell.2009.04.030. Epub 2009 Jul 2.


[Cyclin D1 regulates lung cancer invasion and metastasis].

Li ZL, Shao SH, Jiao F, Yue Z, Ma Y.

Sheng Li Xue Bao. 2012 Feb 25;64(1):55-61. Chinese.


Metastases and Colon Cancer Tumor Growth Display Divergent Responses to Modulation of Canonical WNT Signaling.

Seth C, Ruiz i Altaba A.

PLoS One. 2016 Mar 3;11(3):e0150697. doi: 10.1371/journal.pone.0150697. eCollection 2016. Erratum in: PLoS One. 2016;11(8):e0160904.


GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma.

Kwon OS, Oh E, Park JR, Lee JS, Bae GY, Koo JH, Kim H, Choi YL, Choi YS, Kim J, Cha HJ.

Oncotarget. 2015 Dec 8;6(39):41916-28. doi: 10.18632/oncotarget.6019.


Differential binding of Lef1 and Msx1/2 transcription factors to Dkk1 CNEs correlates with reporter gene expression in vivo.

Lieven O, Dronka J, Burmühl S, Rüther U.

PLoS One. 2014 Dec 29;9(12):e115442. doi: 10.1371/journal.pone.0115442. eCollection 2014.


Brief report: Oct4 and canonical Wnt signaling regulate the cardiac lineage factor Mesp1 through a Tcf/Lef-Oct4 composite element.

Li Y, Yu W, Cooney AJ, Schwartz RJ, Liu Y.

Stem Cells. 2013 Jun;31(6):1213-7. doi: 10.1002/stem.1362.


A unique DNA binding domain converts T-cell factors into strong Wnt effectors.

Atcha FA, Syed A, Wu B, Hoverter NP, Yokoyama NN, Ting JH, Munguia JE, Mangalam HJ, Marsh JL, Waterman ML.

Mol Cell Biol. 2007 Dec;27(23):8352-63. Epub 2007 Sep 24.


Wnt-promoted Isl1 expression through a novel TCF/LEF1 binding site and H3K9 acetylation in early stages of cardiomyocyte differentiation of P19CL6 cells.

Lu H, Li Y, Wang Y, Liu Y, Wang W, Jia Z, Chen P, Ma K, Zhou C.

Mol Cell Biochem. 2014 Jun;391(1-2):183-92. doi: 10.1007/s11010-014-2001-y. Epub 2014 Mar 8.


A novel genome-wide in vivo screen for metastatic suppressors in human colon cancer identifies the positive WNT-TCF pathway modulators TMED3 and SOX12.

Duquet A, Melotti A, Mishra S, Malerba M, Seth C, Conod A, Ruiz i Altaba A.

EMBO Mol Med. 2014 Jul;6(7):882-901. doi: 10.15252/emmm.201303799.


HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression.

Li Y, Bavarva JH, Wang Z, Guo J, Qian C, Thibodeau SN, Golemis EA, Liu W.

Oncogene. 2011 Jun 9;30(23):2633-43. doi: 10.1038/onc.2010.632. Epub 2011 Feb 14.


Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.

Nguyen A, Rosner A, Milovanovic T, Hope C, Planutis K, Saha B, Chaiwun B, Lin F, Imam SA, Marsh JL, Holcombe RF.

Int J Oncol. 2005 Oct;27(4):949-56.


Overexpression of axin downregulates TCF-4 and inhibits the development of lung cancer.

Xu HT, Wei Q, Liu Y, Yang LH, Dai SD, Han Y, Yu JH, Liu N, Wang EH.

Ann Surg Oncol. 2007 Nov;14(11):3251-9. Epub 2007 Sep 1.


Ligand-independent canonical Wnt activity in canine mammary tumor cell lines associated with aberrant LEF1 expression.

Gracanin A, Timmermans-Sprang EP, van Wolferen ME, Rao NA, Grizelj J, Vince S, Hellmen E, Mol JA.

PLoS One. 2014 Jun 2;9(6):e98698. doi: 10.1371/journal.pone.0098698. eCollection 2014.


Differentiation-inducing factor-1 alters canonical Wnt signaling and suppresses alkaline phosphatase expression in osteoblast-like cell lines.

Matsuzaki E, Takahashi-Yanaga F, Miwa Y, Hirata M, Watanabe Y, Sato N, Morimoto S, Hirofuji T, Maeda K, Sasaguri T.

J Bone Miner Res. 2006 Aug;21(8):1307-16.


Knockdown of lymphoid enhancer factor 1 inhibits colon cancer progression in vitro and in vivo.

Wang WJ, Yao Y, Jiang LL, Hu TH, Ma JQ, Liao ZJ, Yao JT, Li DF, Wang SH, Nan KJ.

PLoS One. 2013 Oct 2;8(10):e76596. doi: 10.1371/journal.pone.0076596. eCollection 2013.


Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.

Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B, Shaughnessy JD Jr.

Blood. 2009 Apr 30;113(18):4319-30. doi: 10.1182/blood-2008-08-174300. Epub 2009 Feb 4.


Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.

Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD, Carrasco DE, Zheng M, He H, Tai YT, Mitsiades C, Anderson KC, Carrasco DR.

Proc Natl Acad Sci U S A. 2007 May 1;104(18):7516-21. Epub 2007 Apr 23.

Supplemental Content

Support Center